Articles tagged with Multiple Myeloma
A Phase II clinical trial led by Amir Toor shows promise in providing lasting protection against multiple myeloma progression after a stem cell transplant. The therapy forces cancer cells to express proteins that immune system cells can recognize as foreign, boosting the production of T-cell lymphocytes.
Researchers at VCU Massey Cancer Center have developed a new combination therapy that dramatically increases multiple myeloma cell death. The treatment, involving obatoclax and flavopiridol, promotes apoptosis through different mechanisms, offering new hope for patients with multiple myeloma.
Researchers at John Theurer Cancer Center found carfilzomib to be clinically significant in responding heavily-pretreated patients with relapsed and refractory multiple myeloma. In the multi-center phase IIb study, ORR was 23.7% with median DOR of 7.8 months.
A novel gene variant associated with reduced cholesterol levels has been identified in human populations. Additionally, a new approach for treating Parkinson's disease using embryonic stem cell therapy is proposed. Furthermore, research suggests that brain indoleamine 2,3-dioxygenase 1 (IDO1) plays a crucial role in the concurrence of ...
A new frontline treatment regimen combining carfilzomib, lenalidomide, and low-dose dexamethasone resulted in complete or near complete remission in a majority of patients with newly diagnosed multiple myeloma. The study found that the regimen was well-tolerated, with improved responses as treatment continued.
A three-drug treatment combining carfilzomib, lenalidomide, and low-dose dexamethasone showed rapid and durable responses in newly diagnosed multiple myeloma patients. After at least eight cycles of treatment, 61% had a stringent complete response.
Scientists at NYU School of Medicine identified a pathway that, if deactivated, may help slow the development of multiple myeloma. By targeting this pathway's cellular transcription process, researchers hope to find an effective treatment for the disease.
A new maintenance therapy, lenalidomide, has been shown to improve outcomes for patients with newly diagnosed multiple myeloma who have undergone a stem cell transplant. The study found that patients treated with lenalidomide had a 59% chance of surviving free of disease progression after three years.
The MMRF has partnered with TGen, Spectrum Health, and VARI to provide genomic services and analyze patient samples in a landmark 1000-patient study on multiple myeloma. The study aims to identify specific subgroups of patients and provide insights into the molecular changes that affect disease progression.
A recent study published in Journal of Oncology reveals that MAL3-101, a heat shock protein 70 inhibitor, exhibits potent anti-myeloma effects both in vitro and in vivo. The compound boosts the effectiveness of proteasome inhibitors like bortezomib when used synergistically.
A new study found a possible link between resistance to immunomodulator therapy and the presence of protein cereblon. Lowering cereblon levels allows IMiDs to work properly, suggesting that other mechanisms may play a role in drug resistance.
The John Theurer Cancer Center is participating in a landmark clinical trial to develop personalized treatments for patients with multiple myeloma. The study aims to accelerate translational research into therapeutic breakthroughs, leveraging genomic portraits and tissue sampling.
A phase 3 trial found subcutaneous administration of bortezomib to be as effective as intravenous delivery, but with a better safety profile and lower rates of peripheral neuropathy. Subcutaneous injection could provide an easy home-based treatment option at reduced cost.
A study of nearly 40 tumor genomes has yielded new and unexpected insights into the events that lead to multiple myeloma, a form of blood cancer. The researchers discovered genes never before associated with cancer, as well as genetic mutations disrupting common pathways that trigger cell change.
Researchers sequenced the genome of multiple myeloma in a landmark study, identifying mutations in genes involved in protein translation, blood coagulation, and histone methylation. The findings provide new insights into the disease's development and offer potential directions for targeted therapies.
Scientists at VCU Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The combination regimen of Src inhibitors and Chk1 inhibitors induces cell death in multiple myeloma cells while sparing healthy cells.
A new three-drug combination, CRd, has shown promising results in treating newly diagnosed blood cancer patients, including a high response rate and minimal side effects. The study found that all participants responded to treatment and achieved significant reductions in disease.
Researchers have identified key molecules in multiple myeloma that can trigger expression of the P53 tumor suppressor gene, slowing cell growth and leading to death. The study suggests re-activating these microRNAs could provide a new treatment strategy for the disease.
A study by Mayo Clinic and TGen reveals that DNA methylation is altered with increasing severity in multiple myeloma, leading to the overexpression of oncogenes. The researchers found hypomethylation at specific points of DNA, associated with myeloma development, and suggest it may have prognostic value.
A less intensive bortezomib-based regimen is as effective as the standard treatment for elderly patients with multiple myeloma, but with fewer serious side effects. The regimen resulted in a reduction in peripheral neuropathy and gastrointestinal symptoms while maintaining efficacy.
Researchers identify silencing genes in malignant plasma cells that can be targeted by inhibitors of the Polycomb repressor complex. This approach may lead to new strategies for treating multiple myeloma.
The John Theurer Cancer Center is presenting 16 research abstracts on various areas of oncology during the ASCO Annual Meeting. These studies include Phase I and II trials for multiple myeloma, lymphoma, and cutaneous T-cell lymphoma treatments.
A study of 792 patients with multiple myeloma found that vertebroplasty significantly reduced pain intensity, medication usage, and disability. The procedure improved mobility in nearly half of the patients, who also reported considering vertebroplasty again if needed.
A University of Leeds research project aims to develop new treatments for multiple myeloma patients, using techniques such as injecting cements into the spine. The study seeks to improve quality of life for patients suffering from this incurable bone marrow cancer.
A phase II clinical trial shows that carfilzomib induces a response in 45% of patients with relapsed or resistant multiple myeloma, reducing neuropathy side effects. The drug also demonstrates good tolerability and dose flexibility.
A new three-drug combination has shown a highly effective regimen in treating newly diagnosed patients with multiple myeloma, with partial responses or better seen in all 66 patients. The treatment also resulted in encouraging complete or near-complete responses at 54 percent.
A recent study published in Leukemia suggests that genetic changes in response to environmental toxins may contribute to the development of multiple myeloma. The study found associations between specific DNA sequence variations and an increased risk of bone disease in myeloma patients.
The UK's National Institute for Health and Clinical Excellence (NICE) has approved the use of lenalidomide in patients with multiple myeloma who have received two or more previous therapies. The approval is based on robust data showing that lenalidomide can increase survival by over three months compared to dexamethasone.
A study of 678 pesticide users found a double risk of developing MGUS compared to the general population. The research suggests exposure to certain pesticides increases the risk of this abnormal blood condition, which requires lifelong monitoring as it can lead to multiple myeloma.
A new partnership between UCSF and MMRF aims to accelerate the development of next-generation treatments for multiple myeloma. The initiative will leverage UCSF's expertise in translational research to identify new therapeutic targets and bring them to clinical trials.
A team of researchers developed an antibody targeting FGFR3, which showed potent antitumor activity against human bladder cancer cells and t(4;14)-positive multiple myeloma cells. The antibody also demonstrated activity against normal FGFR3 and mutated forms associated with cancer.
A novel hemodialysis procedure called high cut-off hemodialysis has been shown to restore kidney function and increase lifespan in patients with multiple myeloma, a form of cancer that causes severe kidney failure. In a study of 19 patients who underwent the procedure while receiving chemotherapy, 70% became independent of dialysis.
Phase II trials demonstrate significant activity of pomalidomide in MM and myelofibrosis, with disease improvement or stabilization in 76% of patients. Pomalidomide also shows promise in patients who previously did not respond to REVLIMID therapy.
A landmark analysis found that continuous treatment with Revlimid and dexamethasone improved overall survival and time to disease progression in multiple myeloma patients. Patients who continued therapy had significantly longer overall survival rates compared to those who discontinued treatment after 10 months or less.
The ECOG E4A03 study found that Revlimid plus low-dose dexamethasone improved three-year overall survival rates to 75% in the intent-to-treat population. Continuous therapy also achieved a 91% overall response rate with a high complete response and very good partial response rate.
Early investigational studies show anti-tumor activity in ZOLINZA (vorinostat) and bortezomib combination for relapsed or refractory multiple myeloma. Clinical trials are underway to further evaluate this combination, offering new hope for advanced multiple myeloma patients.
A new combination of medications has improved or stabilized disease in 76% of patients with relapsed multiple myeloma. Pomalidomide combined with dexamethasone showed promising results, with minimal side effects.
Researchers at Johns Hopkins Kimmel Cancer Center found that cancer stem cells in multiple myeloma share properties with normal stem cells and exhibit resistance to chemotherapy. These cells contain high levels of enzymes that neutralize toxins, making them harder to treat.
Results from two Phase I trials demonstrate clinical activity of ZOLINZA (vorinostat) combined with bortezomib in patients with relapsed and/or refractory multiple myeloma. The combination treatment showed partial or minimal responses in 48% of evaluable patients, suggesting potential for further evaluation in randomized clinical trials.
Scientists have developed a retinal flow cytometer that allows for continuous monitoring of circulating cells in a mouse's bloodstream. This technology holds promise for treating multiple myeloma by enabling the testing of chemotherapy agents and treatment strategies.
Findings from two large clinical trials demonstrate significant improvement in patients with multiple myeloma who received Revlimid, an oral cancer drug, compared to those receiving a placebo. The study showed improved median survival and response rates, offering new hope for patients with this challenging disease.
The study found that lenalidomide-dexamethasone combination therapy slows multiple myeloma disease progression and improves overall survival for patients. The treatment resulted in a median time to disease progression of 11.1 months compared to 4.7 months in the placebo group.
A study of 447 patients with multiple myeloma found that thalidomide improved overall survival and response rates compared to standard chemotherapy. The MPT regimen was associated with significantly better outcomes, making it a potential new treatment option for elderly patients.
Researchers identified 17 genes linked to high-risk multiple myeloma, which can predict poor prognosis and guide therapy. The activity of these genes could help categorize patients' risk early, enabling personalized treatment plans.
Emory researchers identify Ribosomal S6 kinase 2 (RSK2) as a critical downstream signaling protein effector of FGFR3 in myeloma cells. RSK2 plays a key role in regulating cell cycle and survival, and targeting it with drugs may be effective in treating multiple myeloma.
A recent study published in Cancer Epidemiology, Biomarkers & Prevention found that obesity is a significant risk factor for developing multiple myeloma. The research, which analyzed data from over 100,000 participants, discovered that individuals with a higher Body Mass Index (BMI) were more likely to develop the disease.
Researchers at Mayo Clinic are testing an engineered measles virus against multiple myeloma, a cancer of the bone marrow with no cure. The study aims to exploit the protein CD46 to target and kill cancer cells.
A clinical trial combining bortezomib with Doxil has shown promising results in treating relapsed or refractory multiple myeloma, a type of bone marrow cancer. The combination treatment demonstrated a better response rate compared to standard therapy alone, with a median time to progression of 9.3 months.
Researchers explored a new approach to maintenance therapy in patients with multiple myeloma, using pamidronate alone or in combination with thalidomide. The study found that ongoing treatment significantly improved cancer-free survival and overall survival probability compared to standard care.
The Mayo Clinic team has developed a consensus statement recommending the use of pamidronate over zoledronic acid for starting therapy, and stopping or reducing bisphosphonates after two years for safe management of multiple myeloma. The guidelines aim to minimize adverse reactions while maintaining effective bone disease prevention.
The FDA approves REVLIMID(R) (lenalidomide) for treating patients with multiple myeloma who have received at least one prior therapy. Key findings include a higher risk of hematologic toxicity and thromboembolic events in patients receiving the combination treatment.
The study found that the average time to disease progression was approximately eight months for patients taking dexamethasone alone, while those on the Thal/Dex regimen had an average progression time exceeding 17 months. Researchers also reported more frequent side effects with the combination therapy.
A new combination therapy of melphalan, prednisone, and thalidomide has shown significant clinical benefits in elderly multiple myeloma patients. The study found higher response rates and longer event-free survival compared to the standard treatment alone, while also increasing risks of thrombosis, neurological effects, and infection.
The International study reported a significant improvement in median time-to-disease progression with REVLIMID plus dexamethasone compared to placebo plus dexamethasone. The best response rate, complete response and near complete response rates were also higher with REVLIMID plus dexamethasone.
The study found that Rev/Dex reduced myeloma cancer protein levels by over half in 91% of patients, with manageable side effects and a rapid response time. This oral treatment offers an attractive alternative to traditional intravenous therapies.
A large study comparing thalidomide and traditional chemotherapy in multiple myeloma patients found that thalidomide was more effective, with 76% of patients achieving at least partial remission. The treatment also had fewer side effects, particularly deep vein thrombosis compared to granulocytopenia.
Researchers found significantly higher risks of non-Hodgkin's lymphoma and multiple myeloma among HCV patients in Sweden. The risk increases with the duration of HCV infection, suggesting that long-lasting infection may contribute to cancer development.
Researchers found that a combination of thalidomide and dexamethasone is as effective as standard intravenous chemotherapy in treating newly diagnosed multiple myeloma. A newer analog, CC-5013 (lenalidomide), showed promise with fewer side effects.
Researchers at Mayo Clinic are investigating thalidomide's potential to combat multiple myeloma through various studies. The findings suggest that the risk of progression to the disease persists even after 30 years, emphasizing the need for ongoing clinical trials.
A new study shows that VELCADE (bortezomib) can significantly extend survival and induce important responses in relapsed and refractory multiple myeloma patients. The median overall survival was 17.2 months, with a 14.1-month duration of response and 15.3-month time to disease progression.